 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...5455565758596061626364...7475» |
- | Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging (clinicaltrials.gov) - Jul 31, 2017
P=N/A, N=100, Recruiting, Sponsor: Center for Eye Research Australia
Initiation date: Apr 2017 --> Sep 2017
- ||| Vabysmo (faricimab-svoa) / Roche
Enrollment closed: STAIRWAY: Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (clinicaltrials.gov) - Jul 31, 2017
P2, N=76, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Apr 2017 --> Sep 2017 Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: MERIT: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (clinicaltrials.gov) - Jul 28, 2017
P3, N=240, Recruiting, Sponsor: JHSPH Center for Clinical Trials
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200 (clinicaltrials.gov) - Jul 25, 2017
P4, N=346, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change: 30g vs 33g Needle for Intravitreal Injections (clinicaltrials.gov) - Jul 24, 2017
P=N/A, N=50, Completed, Sponsor: Wills Eye
Active, not recruiting --> Completed Recruiting --> Completed | N=100 --> 50
- |||| Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Phase II Combination Steroid and Anti-VEGF for Persistent DME (clinicaltrials.gov) - Jul 12, 2017
P2, N=129, Completed, Sponsor: Jaeb Center for Health Research
Recruiting --> Completed | N=100 --> 50 Recruiting --> Completed
- ||| Vabysmo (faricimab-svoa) / Roche
Enrollment closed: AVENUE: A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (clinicaltrials.gov) - Jul 11, 2017
P2, N=273, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (clinicaltrials.gov) - Jul 7, 2017
P3, N=1208, Completed, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| carotuximab ophthalmic (DE-122) / Tracon Pharma, Santen
New P2 trial, Combination therapy, Monotherapy: Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis (clinicaltrials.gov) - Jul 7, 2017
P2, N=51, Recruiting, Sponsor: Santen Inc.
- ||| DS-7080a / Daiichi Sankyo
Enrollment open: Study of DS-7080a for the Treatment of Macular Degeneration (clinicaltrials.gov) - Jul 2, 2017
P1, N=63, Recruiting, Sponsor: Daiichi Sankyo Inc.
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Metastases: Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome (clinicaltrials.gov) - Jun 30, 2017
P1, N=5, Completed, Sponsor: National Eye Institute (NEI)
Active, not recruiting --> Recruiting No longer recruiting --> Completed
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Head-to-Head: DIVERSE: Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema (clinicaltrials.gov) - Jun 29, 2017
P4, N=135, Completed, Sponsor: Novartis Pharmaceuticals
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Xipere (triamcinolone acetonide) / Clearside Biomedical, Bausch Health, Arctic Vision
New P3 trial, Combination therapy: TOPAZ: Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO (clinicaltrials.gov) - Jun 29, 2017
P3, N=460, Not yet recruiting, Sponsor: Clearside Biomedical, Inc.
- || DS-7080a / Daiichi Sankyo
Enrollment change: Study of DS-7080a for the Treatment of Macular Degeneration (clinicaltrials.gov) - Jun 21, 2017
P1, N=63, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
Active, not recruiting --> Completed N=45 --> 63
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP (clinicaltrials.gov) - Jun 20, 2017
P4, N=20, Recruiting, Sponsor: Universidad Autonoma de San Luis Potos
N=45 --> 63 Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: TIDE AMD: Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - May 30, 2017
P4, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: May 2017 --> Sep 2017
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: SALT: Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (clinicaltrials.gov) - May 30, 2017
P4, N=712, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2017 --> Sep 2017 Recruiting --> Active, not recruiting
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial primary completion date: OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov) - May 30, 2017
P=N/A, N=80, Recruiting, Sponsor: Medical University of Vienna
Recruiting --> Active, not recruiting N=20 --> 80 | Trial primary completion date: Dec 2016 --> Dec 2018
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Combination therapy, Monotherapy: Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration (clinicaltrials.gov) - May 25, 2017
P2, N=40, Completed, Sponsor: Medical University of Vienna
N=20 --> 80 | Trial primary completion date: Dec 2016 --> Dec 2018 Recruiting --> Completed
- ||||| Rayoqta (abicipar pegol) / Molecular Partners
Enrollment closed: CDER: A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - May 22, 2017
P3, N=900, Active, not recruiting, Sponsor: Allergan
Recruiting --> Completed Recruiting --> Active, not recruiting
- | levosulpiride / Generic mfg.
New P2 trial: Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov) - May 22, 2017
P2, N=136, Recruiting, Sponsor: Carmen Clapp
- ||||| Rayoqta (abicipar pegol) / Molecular Partners
Enrollment closed: SEQUOIA: Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - May 16, 2017
P3, N=900, Active, not recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Byooviz (ranibizumab-nuna) / Samsung, AffaMed Therap, Biogen
New P3 trial: A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - May 11, 2017
P3, N=704, Not yet recruiting, Sponsor: Samsung Bioepis Co., Ltd.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP (clinicaltrials.gov) - May 10, 2017
P4, N=20, Not yet recruiting, Sponsor: Universidad Autonoma de San Luis Potos
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis (clinicaltrials.gov) - May 9, 2017
P4, N=10, Recruiting, Sponsor: Louis C. Glazer, MD
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Vabysmo (faricimab-svoa) / Roche
Enrollment closed, Enrollment change: BOULEVARD: A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema (clinicaltrials.gov) - May 5, 2017
P2, N=226, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=150 --> 226
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Efficacy and Safety of Lucentis (clinicaltrials.gov) - May 4, 2017
P4, N=21, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=150 --> 226 Active, not recruiting --> Completed
- |||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion, Combination therapy, Monotherapy: EVEREST II: Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (clinicaltrials.gov) - May 4, 2017
P4, N=321, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma, Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study (clinicaltrials.gov) - Apr 28, 2017
P2, N=66, Not yet recruiting, Sponsor: University of Nebraska
Active, not recruiting --> Completed Initiation date: Feb 2016 --> Dec 2017
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial withdrawal: 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME. (clinicaltrials.gov) - Apr 28, 2017
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Initiation date: Feb 2016 --> Dec 2017 N=80 --> 0 | Not yet recruiting --> Withdrawn
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial withdrawal: Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Apr 27, 2017
P2, N=0, Withdrawn, Sponsor: Ohr Pharmaceutical Inc.
N=80 --> 0 | Not yet recruiting --> Withdrawn N=20 --> 0 | Recruiting --> Withdrawn
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change: MAKO: Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD (clinicaltrials.gov) - Apr 27, 2017
P3, N=230, Active, not recruiting, Sponsor: Ohr Pharmaceutical Inc.
N=20 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | N=650 --> 230
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide (clinicaltrials.gov) - Apr 25, 2017
P1, N=20, Recruiting, Sponsor: Soll Eye
Recruiting --> Active, not recruiting | N=650 --> 230 Trial primary completion date: Nov 2016 --> Nov 2019
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron
Phase classification: TITAN: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (clinicaltrials.gov) - Apr 18, 2017
P=N/A, N=236, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Nov 2016 --> Nov 2019 Phase classification: P4 --> P=N/A
- DS-7080a / Daiichi Sankyo
Trial primary completion date: Study of DS-7080a for the Treatment of Macular Degeneration (clinicaltrials.gov) - Apr 17, 2017
P1, N=45, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
Phase classification: P4 --> P=N/A Trial primary completion date: Mar 2017 --> Mar 2018
- | Lucentis (ranibizumab) / Roche, Novartis
New trial: Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab (clinicaltrials.gov) - Apr 13, 2017
P=N/A, N=30, Not yet recruiting, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- | Lucentis (ranibizumab) / Roche, Novartis
New trial: Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=100, Recruiting, Sponsor: Center for Eye Research Australia
- | Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema (clinicaltrials.gov) - Apr 4, 2017
P1/2, N=150, Active, not recruiting, Sponsor: Palmetto Retina Center, LLC
Trial primary completion date: Mar 2017 --> Mar 2018 Trial primary completion date: Nov 2016 --> Apr 2017
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study (clinicaltrials.gov) - Mar 31, 2017
P2, N=126, Completed, Sponsor: Johns Hopkins University
Trial primary completion date: Nov 2016 --> Apr 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Aug 2010
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis (clinicaltrials.gov) - Mar 31, 2017
P4, N=10, Not yet recruiting, Sponsor: Louis C. Glazer, MD
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients (clinicaltrials.gov) - Mar 30, 2017
P3, N=381, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Aug 2010 Active, not recruiting --> Completed
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial primary completion date: RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (clinicaltrials.gov) - Mar 27, 2017
P3, N=230, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=300 --> 230 | Trial primary completion date: Apr 2018 --> Dec 2017
- DS-7080a / Daiichi Sankyo
Enrollment closed: Study of DS-7080a for the Treatment of Macular Degeneration (clinicaltrials.gov) - Mar 13, 2017
P1, N=45, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
N=300 --> 230 | Trial primary completion date: Apr 2018 --> Dec 2017 Recruiting --> Active, not recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Trial primary completion date: Ranibizumab Treatment for Retinal Vein Occlusion (clinicaltrials.gov) - Mar 10, 2017
P=N/A, N=100, Recruiting, Sponsor: Kyoto University, Graduate School of Medicine
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Sep 2019
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: CARE-ROP: Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (clinicaltrials.gov) - Mar 9, 2017
P2, N=19, Completed, Sponsor: University Hospital Freiburg
Trial primary completion date: Sep 2016 --> Sep 2019 Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF (clinicaltrials.gov) - Mar 5, 2017
P2, N=20, Not yet recruiting, Sponsor: Southeast Clinical Research Associates, LLC
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200 (clinicaltrials.gov) - Mar 1, 2017
P4, N=346, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Nov 2016 --> Mar 2017
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date, Head-to-Head: SALUTE-D: Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME (clinicaltrials.gov) - Mar 1, 2017
P3, N=104, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2016 --> Mar 2017 Trial primary completion date: Dec 2016 --> Sep 2017
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: OCEAN: Observation of Treatment Patterns With Lucentis in Approved Indications (clinicaltrials.gov) - Mar 1, 2017
P=N/A, N=5778, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2016 --> Sep 2017 Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: ReCaLL: Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - Feb 23, 2017
P4, N=25, Active, not recruiting, Sponsor: GWT-TUD GmbH
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Nov 2017